Journal of Cancer TherapyHAN CB, MA JT, LI F, et al. Molecular markers for the predic- tion of anti-EGFR monoclonal antibody treatment efficacy in me- tastatic colorectal cancer[ J]. J Cancer Ther, 2011, 2: 675- 682.Molecular markers for the predic-tion of anti-EGFR monoclonal ...
monoclonal antibodycolorectal cancerOver the last decade, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) have been firmly established as essential drugs for the treatment of metastatic colorectal cancer (CRC). Cetuximab and panitumumab have been approved by American and European...
WK Boland,G Bebb - 《Expert Opinion on Biological Therapy》 被引量: 233发表: 2009年 Reply: Comment on |[lsquo]|Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type... The BJC is owned by Cancer Research UK, a...
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015;112:1888-1894.Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody ...
Retreatment with an anti-EGFR monoclonal antibody after prior lines of therapy, including anti-EGFR therapy, may provide an opportunity to shrink the tumor This transcript has been edited for clarity. Anti-EGFR monoclonal antibodies, in particular, cetuximab and panitumumab, are today efficacious treat...
One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments. A 73-year-old male with sigmoid colon ...
amplification, it is essential to distinguish these two quantitative genetic alterations, and we think that the demonstration of a real gene copy number amplification (EGFR/Chr-7 ratio 42) in patients' tumour is more significant with respect to their response to monoclonal antibody-based targeted ...
Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021). Article PubMed PubMed Central Google Scholar Elamin, Y. Y. et al. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of ...
Single chain antibody fragmentCDR graftingmetforminEGFRcancerBackground/Aim: The epidermal growth factor receptor (EGFR) is over-expressed in several types of cancer, and monoclonal antibody therapy has been the strategy that has shown the best results. This study focused on the construction of a ...
Monoclonal antibody (MoAB) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens 来自 scienceopen.com 喜欢 0 阅读量: 46 作者:...